Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.75 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | GLA | P06280 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | NSD2 | O96028 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.57 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.55 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.55 |
| ▸ | PHGDH | O43175 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2378109 | 0.88 | HPGD (0.67) | HPGDTSHRKMT2AGLAGAA | |
| SCHEMBL12311738 | 0.86 | HPGD (0.77) | HPGDTSHRKMT2AGLAGAA | |
| SCHEMBL13161947 | 0.83 | HPGD (1.00) | HPGDKMT2AGAAKDM4EALDH1A1 | |
| SCHEMBL2379228 | 0.83 | HPGD (0.77) | HPGDTSHRKMT2AALDH1A1POLB | |
| SCHEMBL10194842 | 0.82 | HPGD (0.71) | HPGDTSHRKMT2AGLAGAA | |
| SCHEMBL2378698 | 0.82 | PKM (0.75) | HPGDKMT2AGLAKDM4EPKM | |
| SCHEMBL12547416 | 0.82 | HPGD (0.71) | HPGDKMT2AGLAGAAKDM4E | |
| SCHEMBL15652033 | 0.82 | KMT2A (0.64) | HPGDTSHRKMT2AGLAGAA | |
| SCHEMBL3226524 | 0.82 | HPGD (0.71) | HPGDKMT2AGLAGAAKDM4E | |
| SCHEMBL2376730 | 0.82 | HPGD (0.67) | HPGDKMT2AGLAGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | disclosed |
| US-8022205-B2 | Pyrimidine derivatives as PI3K inhibitor and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| US-8022205-B2 | Pyrimidine derivatives as PI3K inhibitor and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| US-8022205-B2 | Pyrimidine derivatives as PI3K inhibitor and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100324284-A1 | PYRROLOPYRIMIDINE DERIVATIVE AS P13K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2010-12-23 | — | — | US | disclosed |
| US-20100324284-A1 | PYRROLOPYRIMIDINE DERIVATIVE AS P13K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2010-12-23 | — | — | US | disclosed |
| US-20100324284-A1 | PYRROLOPYRIMIDINE DERIVATIVE AS P13K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2010-12-23 | — | — | US | disclosed |
| EP-2239261-A1 | PYRROLOPYRIMIDIN DERIVATIVE FOR USE AS PI3K INHIBITOR, AND USE THEREOF | Chugai Seiyaku Kabushiki Kaisha (JP) | 2010-10-13 | — | — | EP | disclosed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | disclosed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | PIK3CA, AKT3, AKT1 | HPGD 1383/4885TSHR 3412/4885KMT2A 2799/4885 |
| US-20100324284-A1 | PYRROLOPYRIMIDINE DERIVATIVE AS P13K INHIBITOR AND USE THEREOF | CSNK1A1, CSK, CSNK1A1L | HPGD 3420/4885TSHR 3447/4885KMT2A 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.